UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Malany, Siobhan
Peddibhotla, Satyamaheshwar
Abrégé
The present disclosure provides compounds of the formulae herein (e.g., Formula (I) and (V)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which are enhancers of particulate guanylyl cyclase (pGC-A). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/428 - Thiazoles condensés avec des carbocycles
2.
NANO2 DODECAFLUOROPENTANE EMULSION AS A CARDIAC ARREST THERAPEUTIC
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Becker, Torben K.
Murphy, Travis W.
Spiess, Bruce Davis
Abrégé
The present invention provides methods for treating cardiac arrest in a subject. The methods involve administering to the subject a pharmaceutical composition comprising NANO2 dodecafluoropentane emulsion.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
3.
BICYCLIC ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Malany, Siobhan
Peddibhotla, Satyamaheshwar
Abrégé
The present disclosure provides compounds of formulae herein (e.g., Formula (I- a) and (I-b)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which are enhancers of particulate guanylyl cyclase (pGC-A). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 33/02 - Antiprotozoaires, p.ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
He, Mei
Barua, Niloy
Ali, Samantha
Abrégé
Described herein is microfluidic droplet generation device for producing multicellular collagen encapsulated spheroids. The multicellular collagen encapsulated spheroids can be used as bio-ink comprising multicellular collagen encapsulated spheroids and a scaffold which can be used to 3D bio-print in vivo-like 3D tumor models. When combined together the 3D multicellular collagen encapsulated spheroid generation platform is adjustable, can be used for high-throughput generation of 3D multicellular collagen encapsulated spheroids and 3D tumor models, and can be used to produce 3D multicellular collagen encapsulated spheroids and 3D tumor models at large scale.
C07D 471/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient deux hétérocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE PENN STATE RESEARCH FOUNDATION (USA)
Inventeur(s)
Sharma, Arun, K.
Singh, Amandeep
Johnson, Hannah
Raza, Asif
Narayan, Satya
Abrégé
Disclosed herein are compounds with protein phosphatase 2A agonizing activity. In some embodiments, the compounds may be used in the treatment of cellular disorders, including cancer. In some embodiments, the compounds are used to treat colorectal cancer, including FOLFOX resistant colorectal cancer.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
C07D 205/02 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles
C07D 213/02 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons comportant trois liaisons doubles
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Valente, Susana, Tavares
Jablonski, Sonia, Mediouni
Jablonski, Joseph
Abrégé
The present disclosure provides compounds of Formulae (I), (II), and (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which may promote the degradation of human immunodeficiency virus type 1 (HIV-1) Tat protein. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases (e.g., HIV) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co- crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
10.
METHODS AND SYSTEMS FOR DETECTING A TARGET AND/OR GENE EDITING USING BRCAS12B AND GENETICALLY ENGINEERED VARIANTS THEREOF
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Jain, Piyush K.
Rananaware, Santosh R.
Nguyen, Long T.
Abrégé
Novel genetically engineered thermostable Cas12b enzymes with lower-than-wildtype thermal stability, lower stability (than wild type) at "normal" reaction temps (around 65 °C), minimally enhanced activity, and/or no cleavage activity than wild type Cas 12b enzymes are provided. Cas12b enzyme variants as described herein can have any one or more of the following mutations: V205L, F208E, D209R, M564C, G859L, S871I, G910E, I925C, T936C, S941E, A946W, Q959I, K960L, L991C, L1085C, L1086K and T874H, D951F. Methods, systems, and kits for detection of target polynucleotide[s] are also provided that can be incorporate or be incorporated in diagnostic techniques (such as RT-LAMP) and gene editing are also provided.
11.
DIRECTED IN VIVO AFFINITY MATURATION OF ANTIBODIES
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Farzan, Michael R.
Ou, Tianling
He, Wenhui
Yin, Yiming
Abrégé
in vivoin vivo affinity maturation, of antibodies. The disclosure also provides a system of affinity maturation of an antibody as well as compositions comprising antibodies generated from methods described herein and polynucleotides encoding such systems.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Johnson, Perry, B.
Abrégé
According to at least one aspect, a method is provided for registering a patient with a medical device for treating the patient. The method includes accessing pose information, wherein the pose information is of a patient, a mixed, reality display, or both, and. wherein the pose information is generated by a. tracking system external to the mixed reality display, registering a pose of a 3D representation of the patient with the medical device using, at least in part, the pose information, and generating, based on results of the registering, a mixed reality visualization of the 3D representation of the patient and the device.
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures
13.
NUCLEASE-FREE GENOME EDITING USING ZINC FINGER DNA BINDING DOMAINS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Bungert, Jorg
Qing, Keyun
Srivastava, Arun
Abrégé
The disclosure relates to recombinant nucleic acids comprising polynucleotides encoding zinc- finger DNA binding domains (ZF-DBDs), and vectors comprising the same. In some embodiments, the encoded ZF-DBDs are capable of targeting a GATA motif in a Bc111A enhancer or, in other embodiments, a gamma-globin promoter. In certain embodiments, the recombinant nucleic acids further comprise a polynucleotide encoding a short hairpin RNA (shRNA), which in some embodiments is capable of targeting a Bc111A mRNA transcript. Methods of promoting globin expression, for example in the treatment of a hemoglobinopathy, comprising the administration of the recombinant nucleic acids of the disclosure and vectors comprising the recombinant nucleic acids of the disclosure to a subject are also described.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
14.
ASSAYS FOR DETECTION OF MAYARO VIRUS AND METHODS OF DETECTION THEREOF
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Fan, Zhonghui Hugh
Alipanahrostami, Morteza
Lednicky, John A.
Abrégé
The present disclosure provide for methods of detecting Mayaro virus in a sample, assays for the detection of the Mayaro virus, and Mayaro virus-specific primers. An assay of the present disclosure can include Mayaro virus (MAYV)-specific primers, such as a MAYV-specific forward inner primer, a MAYV-specific backward inner primer, a MAYV-specific forward primer, and a MAYV-specific backward primer. A method provided in the present disclosure of detecting MAYV in a sample can include adding an amount of the sample to a reaction mixture and amplifying the RNA in the sample using reverse transcription loop-mediated isothermal amplification.
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Porche, Ken
Abrégé
Techniques for treating a subject undergoing spinal surgery include obtaining first data that indicates demographic, medical history or surgery information. A first probability for the subject developing post-operative urinary retention (POUR) is generated by inputting the first data into an input layer of a neural network trained with training data that indicates corresponding information for retrospective patients of spinal surgery and POUR outcomes for those patients. A signal is sent, which indicates a POUR classification for the subject based at least in part on the first probability. The subject is then treated based at least in part on the signal. A binomial regression models trained on a subset of training data is used optionally to produce a second probability. Optionally, the signal indicates a classification based on first or second cutoffs for the two probabilities.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
16.
UNTETHERED INTERNAL GROOVING METHOD AND APPARATUS USING MAGNETIC FIELD
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
PROTODROMICS, INC (USA)
Inventeur(s)
Greenslet, Hitomi
Matsumura, Hiroyuki
Wexler, Adam D.
Abrégé
Various examples are provided related to untethered internal grooving. In one example, a method includes inserting a cutting tool into a tubular workpiece; aligning a driving magnet on an outer surface of the tubular workpiece, the driving magnet including poles aligned with poles of magnets of the cutting tool to position a cutter of the cutting tool against an inner surface of the tubular workpiece; and forming a groove on the inner surface of the tubular workpiece by controlling rotation of the workpiece and linear movement of the cutting tool. The cutting tool can include magnets each including poles on opposite sides and a cutter secured between the magnets.
B24B 19/02 - Machines ou dispositifs conçus spécialement pour une opération particulière de meulage non couverte par d'autres groupes principaux pour meuler des gorges, p.ex. sur des arbres, dans des gaines, des tubes, des éléments de joint homocinétique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Huang, Shuang
Li, Bin
Abrégé
Fibroblast activation protein a (FAP) is a tumor- specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Renata, Hans
Jiang, Yanlong
Abrégé
The present disclosure provides methods of preparing cotylenol, and analogs thereof, comprising a selective hydroxylation catalyzed by a non-heme dioxygenase or cytochrome P450 hydroxylase.
C12P 7/38 - Produits contenant de la cyclopentanone ou de la cyclopentadione
C07C 49/727 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes hydroxyle polycycliques un groupe cétone faisant partie d'un système cyclique condensé
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Jobin, Christian
Newsome, Rachel
Abrégé
Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising a bacterial consortium that promotes interferon (IFN) response in the gut microbiome of a subject and enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
YALE UNIVERSITY (USA)
Inventeur(s)
Jobin, Christian
Newsome, Rachel
Crawford, Jason
Abrégé
Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising one or more compounds that promotes interferon, e.g., interferon gamma (IFNγ), response in the gut microbiome of a subject and/or enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.
C07D 311/12 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 non hydrogénés dans l'hétérocycle substitués en position 3 et non substitués en position 7
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Wang, Eric, Tzy-Shi
Zhou, Yu
Abrégé
Provided herein, in some embodiments, are nucleic acid constructs encoding therapeutic nucleic acids (e.g., miRNAs) of interest comprising one or more alternatively-spliced exons that regulate the expression of proteins or RNAs of interest. Such constructs may in some embodiments be useful for delivery in a recombinant viral vector.
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Yamamoto, Janet, K.
Kariyawasam, Subhashinie
Sahay, Bikash
Abrégé
The disclosure provides a composition comprising a feline coronavirus (FCoV) receptor binding domain peptide and a human severe acute respiratory syndrome coronavirus serotype 2 (SCoV2) receptor domain peptide and uses thereof.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Bandyopadhyay, Sabyasachi
Price, Catherine Elizabeth
Rashidi, Parisa
Tighe, Patrick J.
Abrégé
A method for performing predictive operations, the method comprising receiving a classification dataset comprising clock drawing images, generating, using a classifier, one or more classification outputs, the one or more classification outputs comprising one or more identifications of dementia or non-dementia for respective ones of clock drawing images. The classifier comprises one or more weights based on a latent space associated with a relevance factor variational autoencoder (RF-VAE). The RF-VAE comprises an encoder configured to generate the latent space. The RF-VAE comprises a decoder configured to generate reconstructions of the second one or more clock drawings based on the latent space. The latent space comprises one or more latent dimensions representative of one or more unique aspects of variation associated with the second one or more clock drawings. The one or more latent dimensions comprise minimal total correlation between the one or more latent dimensions and two dimensions.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
AURITA CORPORATION (USA)
Inventeur(s)
Famiglietti, Jack
Sawyer, Wallace Gregory
Smolchek, Ryan
Abrégé
Disclosed herein is a three dimensional (3D) culture system for high-throughput screening with pumpless perfusion. It is a two well flow system where one well has a membrane at the bottom and the other is open. Both wells are connected so the flow is forced in one direction. A dialysis filter membrane can act as a resistor for a system that has a resistance to flow from the 3D culture medium (which is difficult to control) and a resistance from the filter membrane (which is easy to control). The liquid culture media is added to the reservoir well and the 3D culture medium to the sample well. Media will flow through the membrane and the 3D culture medium at a perfusion velocity that is governed in part by the number and size of holes in the membrane.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
26.
COMPOSITIONS, KITS, METHODS, AND METHODS OF ADMINISTRATION RELATING TO EDWARDSIELLA PISCICIDA VACCINE AND/OR ANTIGEN DELIVERY VECTOR SYSTEMS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Curtiss, Iii, Roy
Swain, Banikalyan
Abrégé
Aeromonas hydrophilaEdwardsiella piscicidaEdwardsiella piscicida. In any of these aspects, the vectors are susceptible to antibiotics and do not persist in the environment.
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora pour Bacillus
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Barua, Niloy
Chung, Michael
Guan, Juan
He, Mei
Abrégé
Described are microfluidic high-throughput single cell transwell systems for culturing single paired cells for real time monitoring of exosomes biogenesis, transportation and internalization between paired single cells.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Manohar, Baalaganapathy
Srinivasan, Ravi Shankar
Abrégé
The present disclosure describes various embodiments of a new HVAC system and apparatuses (and related methods) that combine the efficiencies of VRF and VAV systems. An exemplary system comprises a plurality of indoor units located in different zones of a building, each comprising a damper operable to modulate airflow through the indoor unit into a building space and a valve operable to modulate a flow of refrigerant through the indoor unit; an air handling unit having a supply fan that is configured to generate the airflow that is received by the plurality of indoor units; and a controller unit operable to control the damper and the valve simultaneously for each of the plurality of indoor units, wherein the controller unit is operable to control the supply fan and an amount of airflow generated by the supply fan.
F24F 11/74 - Aménagements de commande ou de sécurité - Détails de construction de tels systèmes pour la commande de l’apport en air traité, p.ex. commande de la pression pour la commande du débit d'air ou de la vitesse de l’air
F24F 11/84 - Aménagements de commande ou de sécurité - Détails de construction de tels systèmes pour la commande de la température de l’air fourni en commandant l’apport en fluides échangeurs de chaleur aux échangeurs de chaleur au moyen de valves
F24F 1/0007 - Climatiseurs individuels pour le conditionnement de l'air, p.ex. éléments séparés ou monoblocs ou éléments recevant l'air primaire d'une station centrale Éléments intérieurs, p.ex. ventilo-convecteurs
F24F 3/044 - Systèmes dans lesquels tout le traitement est fait dans une centrale, c. à d. systèmes "tout-air"
29.
STIMULI-RESPONSIVE CHROMOGENIC MATERIALS, METHODS OF MAKING AND METHODS OF USE
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Gao, Fan
Jiang, Peng
Abrégé
In one aspect, the disclosure relates to stimuli-responsive chromogenic compositions that change from a first color to a second color upon application to the skin of a subject and exposure to a stimulus including, but not limited to, heat, light, mechanical rubbing, exposure to electric current, and the like. The compositions include a non-toxic pigment and a cosmetic carrier and do not stain the skin. Additionally, the compositions are stable when stored, even under conditions of elevated temperature. Also disclosed are methods of making the same and methods of treating skin conditions using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Banks, Scott, Authur
Biedrzycki, Adam, Henry
He, Hongjia
Saavedra, Dario, Gonzalo
Perez, Trevor
Sutcliffe, Ninoshka
Zaronias, Katherine
Tse, Joshua
Shroll, Tyler
Abrégé
A method is provided for performing a quadruped unicompartmental stifle arthroplasty. The method includes cutting a plateau of a tibia to form first cut surfaces. The method also includes cutting a medial condyle of a femur to form second cut surfaces. The method also includes aligning openings in a first trial device with the first cut surfaces and forming first holes in the first cut surfaces by passing a drill through the openings in the first trial device. The method also includes aligning openings in a second trial device with the second cut surfaces and forming second holes in the second cut surfaces by passing a drill through the openings in the second trial device. The method also includes mounting a first implant device to the first cut surfaces and mounting a second implant device to the second cut surfaces. A system is also provided for performing the method.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Rader, Christoph
Wilson, Henry D.
Cyr, Matthew
Abrégé
The invention provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize a multiple myeloma cell surface antigen selected from PTPRG, CADM1, ICAM1, and GARS. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications for hematologic malignancies including multiple myeloma and acute myeloid leukemia (AML).
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Welt, Bruce
Abrégé
In one aspect, the disclosure relates to a method for supplementing syngas to produce a precursor composition for synthesis of at least one industrially useful chemical, the method comprising contacting the syngas with an external source of hydrogen. In an aspect, industrially useful chemical comprises methanol and the external source of hydrogen comprises hydrogen produced by steam methane reforming (SMR), hydrogen produced by steam injected onto molten metals, or another hydrogen source. In some aspects, the external source of hydrogen comprises hydrogen produced by a halogen acid contacting scrap metal, wherein the halogen acid can be produced by gasifying a halogen-containing polymer such as, for example, polyvinylchloride (PVC), polyvinylidene chloride (PVDC), or any combination thereof. Also disclosed herein are systems useful for carrying out the disclosed methods.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ding, Yousong
Chen, Manyun
Abrégé
The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysH) to produce compounds of interest. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.
C12P 1/04 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des bactéries
C07C 13/20 - Hydrocarbures monocycliques ou leurs dérivés hydrocarbonés acycliques à cycle hexagonal à cycle du cyclohexène
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
C12N 9/06 - Oxydoréductases (1.), p.ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
C12P 13/00 - Préparation de composés organiques contenant de l'azote
34.
ONSITE SUSTAINABLE SANITATION DEVICES FOR WATER AND NUTRIENT RECYCLING
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Wittmann, Heidemarie
Nawari, Nawari O.
Volk, Michael
Abrégé
Disclosed are various systems, comprising a macerating pump having a solid waste input and configured to convert the waste into a slurry. The system includes a holding tank in fluidic communication with the pump. The system includes a bioreactor in fluidic communication with the holding tank and configured to biochemically break down the slurry into gas(es) and a liquid substrate. Additionally, the system has a biochar filter in fluidic communication with the bioreactor and configured to absorb nutrients from the liquid substrate to produce a treated liquid substrate. The system includes a sterilization unit after the biochar filter, where the sterilization unit is configured to remove a plurality of pollutants from the treated liquid substrate.
C02F 3/08 - Procédés aérobies utilisant des corps de contact mobiles
A01C 23/00 - Dispositifs distributeurs spécialement adaptés pour répandre le purin ou d'autres engrais liquides, y compris l'ammoniaque, p.ex. réservoirs de transport ou voitures arroseuses
C02F 9/20 - Dispositifs de traitement en plusieurs étapes de petite taille portables ou amovibles, p.ex. systèmes de purification de l'eau au point d'utilisation ou pour un laboratoire
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Cao, Yunwei Charles
Jiang, Tian
Abrégé
Disclosed herein are improved broad-spectrum nanozymes for targeting RNA. The disclosed nanozymes are synthesized using recombinant ribonuclease with site-specific cysteine-substituted mutations that can be covalently functionalized with a length-tunable multithiol tether and then loaded onto gold particles through multiple gold-sulfur bonds, or inorganic particles with specific multiple ligand-to-particle-surface bonds. The disclosed nanozymes are also densely loaded with protective DNA oligonucleotides. In some embodiments, the disclosed nanozyme are core-free hollow forms. The removal of the inorganic nanoparticle cores from nanozymes can effectively eliminate the potential long-term toxicity induced by the core, and also creates a cavity for loading and delivery of small molecule drugs.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Zeng, Yong
Wen, Yunjie
Abrégé
In one aspect, the disclosure relates to a system comprising a plurality of microposts protruding from a membrane opposite a solid substrate, wherein the system can be pneumatically actuated to bring the microposts closer to the solid substrate. Also disclosed herein are methods of constructing the system, methods of performing digital bioassays using the disclosed system, and noninvasive methods for detecting diseases and for monitoring the progress of disease treatments using the disclosed system. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Marchant, Jonathan S.
Sprague, Daniel J.
Spicer, Timothy Patrick
Scampavia, Louis
Abrégé
The present disclosure provides novel chemotypes, pharmaceutical compositions thereof, and method of use thereof for treating parasitic infection, including infection caused by parasitic flatworms. The present compounds may be useful as alternatives to praziquantel and may have improved activities against parasitic infections, particularly parasitic flatworm infections.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Narayanan, Ranganathan
O'Brien, William
Livesay, Jason D.
Abrégé
Various examples are provided related to heat transfer enhancement using parametric electrostatic forcing. In one example, a heat transfer system includes a cell including fluids; an aluminum electrode clamped on a first side of the cell; and an ITO-coated glass electrode clamped on a second side of the cell. AC excitation of the aluminum electrode and the ITO-coated electrode produces AC electrostatic fields that resonate the fluids enhancing heat transfer across the cell. The heat transfer system can be operated in microgravity environments without gravity driven buoyancy.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE TRUSTEES OF INDIANA UNIVERSITY (USA)
CORNELL UNIVERSITY (USA)
Inventeur(s)
Zolotukhin, Sergei
Biswas, Moanaro
Marsic, Damien
Rana, Jyoti
De Jong, Ype, P.
Abrégé
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these capsid variants are capable of evading neutralization by the host humoral immune response. The recombinant AAV3B variant proteins and viral particles disclosed herein were identified from a variant AAV3B capsid library that was engineered by making substitutions in only the variable regions of the capsid. Some embodiments of the AAV3B capsid variants disclosed herein comprise the AAV3B-V04 and the AAV3B-V05 variants. Compositions of these variant AAV particles are provided that are useful for transducing and delivering therapeutic transgenes to cells, such as liver cells, and thus treat diseases and disorders pertaining to these cells.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Cao, Yunwei Charles
Xiao, Tianyuan
Lamontagne, Derek
Abrégé
In one aspect, the disclosure relates to nanocrystal solids including a metastable high-pressure phase that is kinetically trapped at ambient conditions and a second phase that is thermodynamically stable at ambient conditions, methods of making the same, and articles including the same. In one aspect, the methods are generalizable across a wide range of materials. In another aspect, the nanocrystal solids may form superconducting or semiconducting materials useful in computing and other fields. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
H01L 31/036 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs caractérisés par leur structure cristalline ou par l'orientation particulière des plans cristallins
41.
NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Hammers, David W.
Sweeney, Lee
Abrégé
The instant disclosure relates to compositions and methods that include NOX4 inhibitors as therapeutic agents capable not only of reducing fibrosis in muscle tissues of subjects having or at risk of developing a muscular dystrophy but also of inducing muscle tissue regeneration, by a mechanism apparently involving activation of fibro-adipogenic progenitor (FAP) cells.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Spicer, Timothy Patrick
Scampavia, Louis
Abrégé
Antibiotic resistance, by definition, occurs when a bacterial pathogen is no longer effectively treated with a particular drug when formerly it was. With the rise in resistance and public awareness of "superbugs," there is a need for new antibiotics, but the number of new antibiotics in the discovery pipeline is roughly a tenth of what it was in the 1980s. Bacterial resistance has emerged, evolved, or has been transmitted to confer resistance to every marketed drug available. Multidrug resistant (MDR) infections have been identified in hospitals that are resistant to all available antibiotics. Resistance is often observed within 2 years of marketing a new antibiotic. Described herein are antibiotic compounds for use in inhibiting bacterial growth and/or treating or preventing a bacterial infection in a subject.
C07D 271/12 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'azote et un atome d'oxygène comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
UNIVERSITY OF HEALTH SCIENCES & PHARMACY IN ST. LOUIS (USA)
Inventeur(s)
Katritch, Vsevolod
Zaidi, Saheem
Majumdar, Susruta
Mclaughlin, Jay P.
Varga, Balazs R.
Che, Tao
Abrégé
This invention reports rational design, synthesis, and characterization of a series of a delta opioid receptor (DOR)-selective bitopic ligands targeting a conserved sodium site in DOR. The design is based on modifications in a selective DOR ligand, Naltrindole, and related indole-to-quinoline derivatives. The discovered compounds are analgesics that are free of addiction and seizure liabilities. Accordingly, a compound of the technology described herein is represented by Formula I:
C07D 491/12 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro- dans lesquels le système condensé contient trois hétérocycles
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Hoh, Brian, Lim
Lucke-Wold, Brandon
Li, Chenglong
Abrégé
Disclosed is a method for treating subarachnoid hemorrhage (SAH) and/or reducing the incidence of subsequent cerebral vasospasm in a patient. The method involves administering a therapeutically effective amount of a first compound or a pharmaceutical composition comprising said first compound to the patient, wherein the first compound comprises a STAT inhibitor compound.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
C07C 311/16 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique
C07D 275/06 - Composés hétérocycliques contenant des cycles thiazole-1, 2 ou thiazole-1, 2 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques avec des hétéro-atomes liés directement à l'atome de soufre du cycle
45.
METHODS AND COMPOSITIONS FOR PRODUCING SELF-AMPLIFYING RNA FOR GENE SILENCING IN PLANTS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Gabriel, Dean, W.
Abrégé
The present invention teaches methods and compositions useful for treating, preventing, or curing pathogen infections of living plants. In particular, the present invention teaches methods of enhancing plant response to pathogen-associated molecular patterns using self-amplifying RNA expressing a dsRNA. The methods and compositions described herein are effective at treating biotrophic pathogens, including Liberibacters.
A01N 65/34 - Rosaceae [famille de la rose], p.ex. fraise, aubépine, prune, cerise, pêche, abricot ou amande
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Nagy, Laszlo
Sweeney, Lee
Hammers, David
Patsalos, Andreas
Abrégé
Methods for treating a disease, condition, or disorder associated with impaired muscle regeneration, including a muscular dystrophy, such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), or limb-girdle muscular dystrophy (LGMD), by administering a PPARγ agonist to a subject. The PPARγ agonist can be one or more thiazolidinediones including, but not limited to pioglitazone and rosiglitazone.
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
47.
FABRICATION OF 3D MULTI-MATERIAL PARTS WITH SPATIALLY TUNABLE MULTI-SCALE POROSITY AND BIOCOMPATIBLE CERAMIC COATING
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Huang, Yong
Ren, Bing
Sole Gras, Marc
Abrégé
Described are systems, apparatuses, and methods for three-dimensional (3D) printing engineered parts having spatially tunable porosity. Printing ink can include metal/ceramic powders, binder(s), sinterable additive(s), polymer(s), porogen(s), and/or solvent(s). Vapor-based phase separation of the printing material causes at least partial solidification of ink to form a green part. A coagulation bath can be used to complete solidification of the green part and remove porogen material(s). Debinding the green part removes polymer(s) and/or porogen material(s) to form a porous, sinterable part. Sintering densifies the debinded part, controls grain growth/size, and improves mechanical properties of the part. Tuning concentration and particle size of porogen in the ink and/or the inter-filament spacing during printing achieves desired porosity and pore size in the finished part. Biocompatible ceramic coating(s) disposed on the part through microbially-induced biomineralization may increase osseointegration performance for bone tissue engineering applications.
B33Y 30/00 - Appareils pour la fabrication additive; Leurs parties constitutives ou accessoires à cet effet
H05K 3/10 - Appareils ou procédés pour la fabrication de circuits imprimés dans lesquels le matériau conducteur est appliqué au support isolant de manière à former le parcours conducteur recherché
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Tran, David
Le, Son Bang
Thai, Nathan
Abrégé
The invention provides compositions comprising a ribonucleotide or ribonucleotides or a deoxyribonucleotide or deoxyribonucleotides encoding at least two cell fate determinants (CFD) selected from the group consisting of PBX2, ACTN2, POU2F1, HAND1, TRIM24, GATA4, PBX1, ZBTB39, HAND2, IKZF4, NR0B2, NACA2, SMYD1, JUP, NEUROD1, CKMT2, TSHZ2, MITF, MYOCD, and PPARGC1B. The compositions are useful in the treatment of cardiac disorders and in reprogramming a mesenchymal stem cell (MSC) to an autologous induced cardiomyocyte (iCM).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Byrne, Barry John
Corti, Manuela
Abrégé
Described are viral vectors, compositions, kits, and methods or using the vectors, compositions, kits to modulate immune response in a subject. The viral vectors include therapeutic recombinant adeno-associated viruses (rAAVs) and tolerance inducing gene therapy vectors. The therapeutic rAAVs and tolerance inducing gene therapy vectors can be used to deliver one or more therapeutic nucleic acids to the subject. The tolerance inducing gene therapy vectors induce immune-specific tolerance to the therapeutic rAAVs to improve efficacy of the therapeutic rAAVs and allow for multiple administrations of the therapeutic rAAVs with little or no associated immune response to the therapeutic rAAVs. The therapeutic rAAVs can be used to administer a therapeutic effect to the subject.
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
50.
SALMONELLA VECTORED THERAPIES FOR TREATMENT OF CANCER
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Curtiss, Roy
Wang, Shifeng
Abrégé
SalmonellaSalmonella cell (GMSC) engineered to exhibit specific targeting to cells and regulated delayed lysis in vivo, the GMSC comprising a first heterologous nucleic acid that encodes a first gene product that causes the GMSC to be selectively localized to and/or internalized by a target cell in vivo and a second heterologous nucleic acid that encodes a second gene product that facilitates killing of the target cells following internalization.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Zarrinpar, Ali
Duarte, Sergio
Battula, Narendra
Willman, Matthew, F.
Abrégé
A system for the measurement of cell-free DNA that comes off of a kidney pump (perfusate) prior to transplantation to evaluate the viability of the organ (quantification of donor injury) and the risk for primary graft dysfunction after transplantation. This use of cfDNA does not require sequencing just quantification. A device that would connect to a kidney pump and directly measure the cfDNA and analyze it.
A61M 1/16 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang avec membranes
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
52.
BIOCATALYTIC SYNTHESIS OF UNNATURAL MYCOSPORINE-LIKE AMINO ACIDS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ding, Yousong
Chen, Manyun
Abrégé
The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysD) to produce compounds of interest using unnatural amino acids or amine containing substrates. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.
C12P 1/04 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des bactéries
C12P 13/00 - Préparation de composés organiques contenant de l'azote
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/77 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora pour Brevibacterium
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
53.
APPARATUS AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR DEEP BRAIN STIMULATION (DBS)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Cagle, Jackson, N.
De Hemptinne, Coralie
Abrégé
A method and apparatus are provided for determining stimulation parameters for DBS. The method includes receiving first data indicating a value of a local field potential (LFP) over a first time period from first contacts positioned adjacent a brain region. The method further includes receiving third data indicating a value of a LFP over second time periods from the first contacts, where the brain region is stimulated by second contacts over second time periods based on stimulation parameter values. The method further includes determining a frequency band encompassing a difference between a first frequency spectrum of the first data and a second frequency spectrum of the third data. The method further includes determining a value of the second frequency spectrum over the frequency band for each stimulation parameter value. The method further includes determining a value of an optimal stimulation parameter based on the value of the second frequency spectrum and each stimulation parameter value.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Disney, Matthew D.
Abrégé
The present disclosure provides compounds of the formulae herein (e.g., Formulae (I) or (II)), and pharmaceutically acceptable salts thereof, which are degrader compounds of Quiescin Sulfhydryl Oxidase 1 (QSOX1) mRNA. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases. Related compounds and methods useful in probing RNA targets and studying molecular recognition patterns between RNA and ligands are described.
C40B 20/04 - Identification des éléments d'une bibliothèque au moyen d'une étiquette, d'un marqueur ou d'un autre identificateur lisible ou détectable, p.ex. procédés de décodage
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Maupin, Julie A.
Jia, Huiyong
Abrégé
Presented arc two new methods, single primer extension reaction (SSPER) and reduce recycle PCR (rrPCR). These methods have a step that easily removes the oligonucleotide primer(s) after the first reaction, thus, allowing for the addition of a second reaction in chronological sequence to generate and isolate the appropriate DNA product with the site-directed mutation(s). A high efficiency of the methods is demonstrated by generating all ten site-directed mutations and six paired combinations of these mutations on four plasmid DNA templates ranging from 10 to 12 kb and 57 to 59% GC-content at a rate of 50-100%. The methods are i) highly accurate allowing for screening of plasmids by DNA sequencing, ii) streamlined to generate the mutations within a single day, iii) cost-effective in requiring only two primers and two enzymes (Dpnl and a proofreading DNA polymerase), iv) straightforward in primer design, and v) applicable for both large and small plasmids.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
56.
SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Renata, Hans
Amatuni, Alexander
Adibekian, Alexander
Shuster, Anton
Abrégé
One aspect of the invention is any compound, or salt thereof, described herein. Another aspect is a method of treating a disease, disorder, or symptom thereof, in a subject, comprising administration to the subject of a compound, or salt thereof, herein. Another aspect is a method of inhibiting a proteasome in a subject, comprising administration to the subject of a compound, or salt thereof, herein. Another aspect is a method of making a compound, or salt thereof, described herein using one or more reagents, chemical transformations, or chemical intermediate compounds as described herein.
C07D 245/02 - Composés hétérocycliques contenant des cycles de plus de sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p.ex. Pro, His, Trp
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Hwang, Dobeen
Rader, Christoph
Abrégé
The present invention provides antibody compounds that contain a substitution of cysteine for the reactive lysine residue (lysine 93 by Kabat numbering) in the hydrophobic cleft (38C2_Cys). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered cysteine residue in the 38C2_Cys variant antibody. Further provided in the invention are therapeutic applications of the compounds.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Davidson, Cullen Lee Garrett
Lott, Megan
Olson, Rebecca
Pedro, Diego Ivan
Sawyer, Wallace Gregory
Sumerlin, Brent S.
Abrégé
The present disclosure provides for compositions including at least one type of watersoluble polymer having a molecular weight of about 10 kDa to 10,000 kDa, methods of making the water-soluble polymer, structures having the water-soluble polymer disposed thereof, and methods of use thereof. The present disclosure provides for branched and hyperbranched water-soluble polymers and methods of making branched and hyperbranched water-soluble polymers.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Bowers, Clifford Russell
Abrégé
The disclosure relates to systems and methods for preparing precursor molecules including a hyperpolarized heteronucleus. The precursor molecules can be metabolites or derivatives. Heteronucleus hyperpolarization can be achieved by hydrogenating a carbon-carbon bond with parahydrogen, followed by transferring hyperpolarization from a parahydrogen to another hydrogen using adiabatic passage, after which an INEPT, selective INEPT, or MINERVA pulse sequence can be used to transfer hyperpolarization to a heteronucleus. Also disclosed are MRI contrast agents including the small molecules as well as a method of detecting a disease state associated with abnormal activity of a precursor molecule metabolite in a subject, the method including at least the step of administering a metabolite having a hyperpolarized heteronucleus to the subject and detecting the metabolite in the subject. In some aspects, the disclosed systems can incorporate an ultrasonic spray nozzle for forming droplets in order to better control the rate of substrate hydrogenation.
A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire (RMN); Préparations de contraste pour l'imagerie par résonance magnétique (IRM)
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Boehlein, Susan, Kim
Hudalla, Gregory, A.
Liu, Renjie
Park, Junha
Resende, Marcio, F.
Abrégé
Provided are formulations that utilize phytoglycogen as a stabilizing excipient. The phytoglycogen may be from maize, or more specifically maize harboring a mutation on the sugaryl (su1) gene. Also provided are methods of stabilizing a protein active ingredient by formulation the protein active ingredient with phytoglycogen.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Hudalla, Gregory, Allan
Liu, Renjie
Abrégé
Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are protein carrying granules. Further provided herein, are methods of making each of the co-assembling peptides and granules.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
ENTRINSIC, INC. (USA)
Inventeur(s)
Vidyasagar, Sadasivan
Sasidharan, Anusree
Grosche, Astrid
Kumar, Ashok V.
Peethambar, Breman Anil
Varier, Keerthi
Hiregange, Arun
Abrégé
A system including a tissue bath; a portion of intestine positioned within the tissue bath, the portion of intestine having a first end and a second end; a pump coupled to the first end of the portion of the intestine and configured to pump a fluid through the portion of intestine; a light source positioned to illuminate the portion of intestine, a camera positioned to capture a stream of images showing movement of the portion of intestine; and a computing system coupled to the camera, the computing system including: a processor, and a memory storing instructions causing the processor to: receive the stream of images, identify a location along the portion of intestine in each image of the stream of images in real time, and measure an edge width at the location along the portion of intestine in each image of the stream of images in real time.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Pan, Jing
Tai, Yongchen
Abrégé
Apparatuses and corresponding methods are provided for determining molecular properties of a molecule. To determine molecular properties of the molecule, a molecule library comprising the molecule is generated, a focused library comprising the molecule is generated by filtering the molecule library; the focused library is attached to a flow cell of the imaging instrument; and a fluid control module of the imaging instrument is controlled to incubate the flow cell with a fluid comprising labelled target molecules. A light source module and an imaging module of the imaging instrument are operated in a selected operational mode such that the light source module illuminates the flow cell and the imaging module captures light generated by fluorescence by the labelled target molecules within the flow cell. Image data is generated based on the captured light and the imaging data is analyzed to determine molecular properties of the at least one molecule.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Sayour, Elias
Mendez-Gomez, Hector, Ruben
Geffrard, Hilary
Qdaisat, Sadeem
Sawyer, Wallace, Gregory
Abrégé
The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL10.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORTED (USA)
Inventeur(s)
Mccurdy, Christopher, R.
Abrégé
Described herein are new dual sigma receptor and dopamine transporter small molecule antagonists. As these compounds are antagonists of both sigma receptors and dopamine transporters, these compounds dose-dependently antagonize stimulant self- administration and also diminish the effects of stimulant effects on dopamine level, thus indicating minimal abuse liability.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Brantly, Mark, Louis
Aranyos, Alek
Flagg, Tammy, O.
Abrégé
Binding proteins that bind Z-alpha-1 antitrypsin (Z-AAT) and M-alpha-1 antitrypsin (M-AAT) are provided, as well as kits comprising the binding protein(s). The disclosure also provides a method for detecting Z-alpha-1 antitrypsin (Z-AAT) in a subject, a method of characterizing delivery of M-AAT to a subject suffering from AAT deficiency, and a method of detecting AAT deficiency in a subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Cui, Lina
Chen, Zixin
Liu, Jun
Abrégé
in vivo in vivo imaging modalities including near-infrared (NIR), positron emission tomography (PET) and magnetic resonance (MR) imaging and the methods of use thereof.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
AAVANTIBIO, INC. (USA)
Inventeur(s)
Byrne, Barry, John
Corti, Manuela
Casy, Widler
Abrégé
The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product in order to ameliorate one or more symptoms of the cardiomyopathy in a subject. In several embodiments, the disclosed methods and compositions relate to recombinant adeno-associated virus particles encoding human RBM20 in order to treat cardiomyopathies, including dilated cardiomyopathy.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
71.
METHODS AND COMPOSITIONS FOR TREATING TNNT2 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
AAVANTIBIO, INC. (USA)
Inventeur(s)
Byrne, Barry, John
Corti, Manuela
Casy, Widler
Cockrell, Adam
Abrégé
The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product to host in order to ameliorate one or more symptoms of the cardiomyopathy. In several embodiments, the methods and compositions relate to recombinant adeno-associated virus particles encoding human TNNT2 in order to treat cardiomyopathies, including dilated cardiomyopathy or hypertrophic cardiomyopathy.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/67 - Méthodes générales pour favoriser l'expression
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
72.
COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Martemyanov, Kirill
Sutton, Laurie
Abrégé
Described are compositions, combinations, and methods of using the compositions and combinations for use in treating depression. The compositions and combinations comprise a GABA B receptor agonist and an alpha-2 adrenergic receptor agonist.
A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
A61K 31/185 - Acides; Leurs anhydrides, halogénures ou sels, p.ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Deleyrolle, Loic
Mitchell, Duane
Huang, Jianping
Jin, Linchun
Abrégé
Described are chimeric lactate receptors that act a molecular switches. A chimeric lactate receptor comprises a lactate receptor linked to one or more intracellular signaling domains. Also described are nucleic acids encoding the chimeric lactate receptors, T cell expressing the chimeric lactate receptors, and method of using the T cells to treat cancer.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Byrne, Barry, John
Corti, Manuela
Abrégé
The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product in order to ameliorate one or more symptoms of the cardiomyopathy in a subject. In several embodiments, the disclosed methods and compositions relate to recombinant adeno-associated virus particles encoding human TMEM43 in order to treat Arrhythmogenic cardiomyopathy.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
75.
METHODS AND SYSTEMS FOR PAMLESS DETECTION OF NUCLEIC ACIDS WITH TYPE V CRISPR/CAS SYSTEMS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Jain, Piyush K.
Rananaware, Santosh
Vesco, Emma
Shoemaker, Grace M.
Sandoval, Luke Samuel
Abrégé
Described herein are CRISPR/Cas-based methods, systems, compositions, and kits relating to the detection of one or more target polynucleotides that do not require the presence of a PAM sequence. In certain aspects, methods, systems, compositions, and kits utilize Cas12a, customized guide RNA, and an isothermal amplification buffer for polynucleotide detection. In certain aspects, methods, systems, compositions, and kits as described herein can detect SARSCoV-2, and variants thereof; hepatitis C virus (HCV), and variants thereof, human immunodeficiency virus (HIV) and variants thereof, among others. In certain aspects, methods, systems, compositions, and kits can be employed in a point-of-care setting without the use of a thermocycler.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Martemyanov, Kirill
Grill, Brock
Abrégé
Described are compositions and methods for increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Ptchd1 or neuronal cholesterol.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Veige, Adam, S.
Evans, Austin
Abrégé
Disclosed are methods and apparatus for forming three-dimensional articles from using layered gaseous deposition (LGD), comprising (a) depositing a solution comprising a catalyst and a solvent on a substrate to form a printed design, (b) contacting the printed design with a gas comprising a plurality of monomers comprising alkynes, alkenes, or a combination, forming a first layer of solid polymer; and (c) advancing the substrate away from the deposition means to form the three dimensional article.
B29C 64/159 - Procédés de fabrication additive n’utilisant que des substances gazeuses, p.ex. un dépôt en phase vapeur
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
UNIVERSITY OF FLORIDA RESEARCHFOUNDATION, INCORPORATED (USA)
Inventeur(s)
Ranum, Laura
Nguyen, Lien
Guo, Shu
Abrégé
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of C9orf72 negative sporadic amyotrophic lateral sclerosis (C9- sALS). In some embodiments, the disclosure relates to identifying a subject as having C9orf72 negative (C9-) sALS by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the methods and compositions of the disclosure identify certain gene or genes which comprise mutation(s) leading to the expression of the detected RAN proteins, and which were previously unknown to be associated with sALS. In some embodiments, said gene(s) can be used to identify or diagnose subjects having, suspected of having, or at risk of developing sALS which is unrelated to expansion mutations within the C9orf72 and/or SCA36 genetic loci (e.g., C9- sALS). In some embodiments, the disclosure relates to methods of treating C9- sALS by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
79.
COMPOSITIONS AND METHODS FOR SUPPRESSION OF FLOWERING IN SUGARCANE AND ENERGYCANE
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Altpeter, Fredy
Kannan, Baskaran
Abrégé
Saccharum . Saccharum Saccharum plants, such as sugarcane or energycane. Target genes were isolated from the sugarcane and energycane cultivar and a conserved sequence between these cultivars and closely related species was chosen to design intron-hairpin RNA constructs for RNAi suppression or sgRNA expression constructs for targeted mutagenesis. Recombinant DNA vectors were introduced into sugarcane by biolistic gene transfer and transgenic plants were regenerated and selected, vegetatively propagated for replicated field testing. These genetically modified plants produce significantly elevated biomass and recoverable sugar yield under replicated field conditions relative to a similar plant in which the FT4, FT8, and/or FT10 gene have not been disrupted, when grown under the same conditions.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Yan, He
Zeng, Yong
Abrégé
Described herein are methods, compositions, and kits relating to the detection of one or more polynucleotides, in particular miRNAs. In certain aspects, methods, systems, compositions, and kits utilize Cas12a for polynucleotide detection, in particular miRNAs. In aspects the methods, systems, compositions, and kits utilize Cas12a for detection of polynucleotide targets in a single pot reaction.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
82.
SMALL MOLECULE STAT3 INHIBITOR FOR TREATING TRIPLE NEGATIVE BREAST CANCER
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Lin, Jiayuh
Pan, Li
Li, Chenglong
Abrégé
Methods of using the small molecule STAT3 inhibitor LLL12B in the treatment of cancer, such as triple-negative breast cancer (TNBC) and pancreatic cancer, either alone or in combination with additional therapeutic agents, such as PARP inhibitors and CDK inhibitors, are provided.
C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
83.
METHOD, APPARATUS, AND SYSTEM FOR MANUAL SURGICAL DISSECTION
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Jang, Eugene S.
Scarborough, Mark Thomas
Gibbs, C. Parker
Spiguel, Andre
Abrégé
Provided herein is a method, apparatus, and system for precise dissection of soft tissue, and more particularly, to the use of a hand-worn device to facilitate dissection while providing tactile feedback to a wearer. Methods include receiving an indication of resistance between at least two leads; establishing a mode of operation based on the indication of resistance; receiving an indication of activation; and providing a current at a voltage and duty cycle based on the mode of operation established to at least one of the at least two leads for electrosurgery. The at least two leads of some embodiments include two electrosurgical devices, where receiving an indication of resistance between the two electrosurgical devices includes receiving an indication of infinite resistance between the two electrosurgical devices, and where the mode of operation is established as bipolar dissection between the two electrosurgical devices.
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Liechty, Kenneth
Malany, Siobhan
Peddibhotla, Satyamaheshwar
Zgheib, Carlos
Abrégé
Small molecule CXC chemokine receptor type 4 (CXCR4) agonists are disclosed, methods of their manufacture, and uses thereof, in particular to improve healing and reduce the risk of injury for wound healing in diabetes.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Alwisy, Aladdin
Abrégé
A multifunctional end effector robotic system of the present disclosure comprises a mounting plate of a multifunctional end effector that is configured to couple to an arm of a robot; and a plurality of functional components of the multifunctional end effector. The plurality of functional components comprises a work piece holding assembly that is configured to perform clamping or suction actions to a work piece; a fastener gun component that is configured to attach a fastener to a work piece; and/or a spray component that is configured to perform spraying or extruding of materials on a work piece. The multifunctional end effector robotic system further comprises a power control box of the multifunctional end effector that is configured to supply power to the plurality of functional components. Other systems and methods are also provided.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Martemyanov, Kirill
Stoveken, Hannah
Spicer, Timothy Patrick
Scampavia, Louis
Abrégé
Described are GPR139 modulators, agonists and antagonists of GPR139 activity and/or GPR139 signaling. Pharmaceutical compositions comprising the GPR139 modulators are also described. The GPR139 modulators and pharmaceutical compositions comprising the GPR139 modulators can be used to enhance opioid analgesic efficacy, suppress symptoms associated with opioid withdrawal, decrease opioid addiction or dependence, or treat neuropsychiatric disorders.
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Shenvi, Ryan
Woo, Stone
Bohn, Laura
Zielke, Florian
Abrégé
The present invention provides a process for the synthesis of Galbulimima alkaloid 18 (GB18). Also provided are compounds that are useful as opioid receptor antagonists and agonists.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Veige, Adam S.
Zeng, Yong
Spiess, Bruce Davis
Orta Santana, Amanda
Yan, He
Abrégé
Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described along with a system for determining the level of ATIII in a point-of-care setting. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. A system and apparatus are provided that determine the level of ATIII in a point-of-care setting in an efficient manner to facilitate determining a dosage or heparin or ATIII to administer to a patient.
G01N 33/86 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir le temps de coagulation du sang
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p.ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Kim, Stanley E.
Protopsaltis, Dimitri
Sherman, Mike
Abrégé
Provided herein is a method, apparatus, and system for a locking fastener, and more particularly, to a locking fastener system whereby a fastener can be inserted into a complementary hole to any depth along a length of the fastener and secured with a turn of less than half of a rotation of the fastener. A system described herein includes a body defining a hole, the hole extending along a central axis defined through a center of the hole; a fastener having a fastener shaft where the fastener shaft defines two opposing unthreaded faces and two opposing threaded faces, where the fastener is configured to be inserted into the hole in an insertion orientation without rotation, and where the fastener is configured to become locked within the hole in response to rotation of the fastener from the insertion orientation to a locked orientation.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (USA)
Inventeur(s)
Veige, Adam, S.
Yadav, Rinku
Abrégé
Provided herein are catalysts for polymerization of linear alkynes to cyclic poly(alkynes), and methods of making and using same. For example, provided herein are compounds of formula (I), or dimers thereof:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Kondratov, Oleksandr
Ukhanova, Maria
Zolotukhin, Sergei
Abrégé
Disclosed herein are recombinant AAV variant (e.g., variant serotype 5 (AAV5)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce adult stem cells and neurons. Viral particles containing these capsid variants are capable of enhanced transduction of mammalian mesenchymal stem cells and neurons. The recombinant AAV5 variant proteins and viral particles disclosed herein were identified from a variant AAV5 capsid library that was engineered by making substitutions in variable regions of the capsid. Compositions of these variant AAV5 particles are provided that are useful for transducing and delivering therapeutic transgenes to cells, such as mesenchymal stem cells, and thus treat diseases and disorders pertaining to these cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
92.
BRUTON'S TYROSINE KINASE INHIBITORS AS ANTIVIRAL AGENTS
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Mcintosh, Michael
Bhaduri-Mcintosh, Sumita
Abrégé
Use of pharmaceutical compositions comprising Bruton's tyrosine kinase (BTK) inhibitors in decreasing Epstein-Barr Virus lytic cycle or switch from latency to lytic cycle are described. The pharmaceutical compositions can be used to prevent or reduce the risk of developing an EBV-positive lymphoproliferative disease (LPD), EBV-associated malignancy, or pre-malignancy, including in immunosuppressed subjects.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Jang, Eugene S.
Scarborough, Mark Thomas
Gibbs, C. Parker
Spiguel, Andre
Abrégé
Provided herein is a method, apparatus, and system for the removal of benign and malignant lesions, and more particularly, to the use of image analysis and three-dimensional modeling for the excision of skin-based, subcutaneous, or deep lesions with a precise and reproducible margin of tissue around the lesion. Methods include: obtaining images of a tumor within a patient; determining a size and shape of a tissue mass to be resected including the tumor based on the images; generating a three-dimensional model of a resection tool for resecting the mass of tissue to be resected based on the size and shape of the tissue mass as well as nearby vital structures and anatomic landmarks; and providing for three-dimensional manufacture of the resection tool.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,, INCORPORATED (USA)
SHANGPHARMA INNOVATION (USA)
Inventeur(s)
Kamenecka, Theodore, Mark
Solt, Laura, A.
He, Yuanjun
Lizarzaburu, Mike
Bookser, Brett, C.
Abrégé
The present disclosure provides compounds and their pharmaceutical compositions as selective agonists of REV-ERBα. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.
C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
C07D 209/08 - Indoles; Indoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Srinivasan, Ravi Shankar
Nawari, Nawari O.
Abrégé
The present disclosure presents a system and related methods for automated determination of land development code performance. One such method comprises performing, using at least one hardware processor, design model validation, wherein design model validation comprises entering land development permit application file information and checking the land development permit application file information against relevant land development codes; performing exchange model code checking using a plurality of exchange models; performing conformance checking by receiving a request from the exchange models and passing the land development permit application file information to design checking modules configured to check land development code, ordinance, and regulation provisions and one or more codes, ordinances, and regulations per local, state, national or international requirements; and performing compliance reporting based on input provided from the design checking modules.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Sawyer, Wallace Gregory
Sumerlin, Brent S.
Nguyen, Duy T.
Bowman, Jared Ian
Abrégé
The present disclosure provides for microgels, microgel compositions, methods of making microgels and microgel compositions, methods of using microgels and microgel compositions, and the like. The present disclosure provides for microgel compositions having a plurality of agent functionalized microgel particles that have a neutral charge. The agent functionalized microgel particles can be made of a polymer, where the polymer can be functionalized with an activated functional group that are quenched or bonded to at least one type of agent through the activated functional group. The agent functionalized microgel particles can have a longest dimension of about 5 to 150 µm and an aspect ratio of about 1 to 1.5.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
Inventeur(s)
Leon, Francisco
Dunford, Paul
Miller, Diana
Byrne, Barry, John
Corti, Manuela
Abrégé
Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a BTHS gene therapy, an effective amount of B cell inhibitor that is non-depletional. Related compositions are also provided.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07D 211/68 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
A61K 31/4412 - Pyridines non condensées; Leurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
MISSISSIPPI STATE UNIVERSITY (USA)
Inventeur(s)
Subhash, Ghatu
Whittington, Wilburn
Abrégé
The present disclosure relates to compact waveguide impact devices. One example includes a branching compact mechanical waveguide that has at least one input impact location and at least one input impact location output impact point. The compact waveguide impact device also includes at least one input impact component. A controller device activates the at least one input impact component to strike the at least one input impact location according to an input impact pattern, thereby producing a desired output impact pattern.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Costin, Aaron
Mcnair, Janise
Abrégé
The present disclosure provide multi-access edge computing systems and methods. One such system comprises a plurality of sensor devices that are configured to collect construction site sensor data and transmit the sensor data to a local computing system that is configured to combine the sensor data with user feedback data and transmit the combined data to an edge computing system. The edge computing system is configured to process the combined data and transmit the combined data to a cloud computing system, where the cloud computing system that is configured to process the transmitted data from the edge computing system. The edge computing system or the cloud computing system is configured to execute a site risk prediction application and predict a hazard within a construction site based on the collected construction site sensor data and generate an output signal to equipment operating at the construction site.